Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) shot up 10% during trading on Tuesday after Canaccord Genuity Group raised their price target on the stock from $35.00 to $39.00. Canaccord Genuity Group currently has a buy rating on the stock. Heartflow traded as high as $34.60 and last traded at $34.58. 161,873 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 501,088 shares. The stock had previously closed at $31.43.
Other equities analysts have also recently issued reports about the stock. Piper Sandler assumed coverage on shares of Heartflow in a report on Tuesday, September 2nd. They issued an "overweight" rating and a $38.00 target price on the stock. Wall Street Zen upgraded shares of Heartflow to a "hold" rating in a research report on Saturday, August 16th. Morgan Stanley assumed coverage on shares of Heartflow in a report on Tuesday, September 2nd. They issued an "equal weight" rating and a $35.00 target price on the stock. Zacks Research raised shares of Heartflow to a "hold" rating in a research note on Wednesday, September 3rd. Finally, Stifel Nicolaus initiated coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They set a "buy" rating and a $35.00 target price for the company. Four analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $36.60.
View Our Latest Research Report on HTFL
Heartflow Stock Performance
Heartflow (NASDAQ:HTFL - Get Free Report) last issued its quarterly earnings data on Friday, September 19th. The company reported ($1.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($1.26). The company had revenue of $43.42 million during the quarter, compared to analyst estimates of $43.20 million.
About Heartflow
(
Get Free Report)
We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Heartflow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heartflow wasn't on the list.
While Heartflow currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.